je.st
news
Tag: bowel
Triple W to Preview DFree Bowel Sensor at CES 2020
2020-01-02 15:00:00| Nonwovens Industry Breaking News
Wearable device for bowel incontinence monitors via ultrasound
Tags: ces
preview
triple
sensor
APHA Report: PRRS, Bowel Oedema, Bacterial Joint Infections
2015-04-17 02:00:00| ThePigSite - Industry News
UK - The Animal and Plant Health Agency (APHA) has reported incidents including respiratory disease involving porcine reproductive and respiratory syndrome (PRRS), sudden deaths from bowel oedema and bacterial joint infections with underlying PRRS in its Pig Disease Surveillance Monthly Report for December 2014.
Tags: report
joint
infections
bacterial
J&J in deal to develop microbiome drug for bowel diseases
2015-01-13 15:23:06| Food - Topix.net
Johnson & Johnson on Tuesday announced a licensing deal with Vedanta Biosciences to develop the privately held company's lead microbiome-based drug candidate for inflammatory bowel disorders, such as Crohn's disease and ulcerative colitis. J&J said Vedanta will receive an undisclosed upfront payment and would be eligible to receive up to $241 million for achieving development and commercial milestones.
Tags: deal
develop
drug
diseases
Johnson & Johnson licenses Vedanta's bowel disease drug
2015-01-13 15:05:06| Biotech - Topix.net
Johnson & Johnson has licensed a potential treatment for inflammatory bowel diseases from a company developing therapies that alter interactions between the immune system and microbes in the body. J&J's Janssen Pharmaceutical Companies unit says Vedanta Biosciences of Boston could receive up to $241 million, including an upfront payment and additional ones if a medicine gets approved for a bowel disease such as ulcerative colitis or Crohn's disease.
Tags: drug
disease
johnson
licenses
J&J buys bowel drug license option from Isis Pharma for $835 million
2015-01-06 03:00:04| Food - Topix.net
Johnson & Johnson will pay Isis Pharmaceuticals Inc up to $835 million for the option to license three drugs targeting autoimmune diseases in the bowel. Isis Pharmaceuticals said it will receive $35 million in an upfront payment and will be eligible to receive royalties on sales of the drugs.
Tags: million
license
option
drug